Verastem Newsroom

Optimistic Buy Rating: Strong Phase 2 Results and Regulatory Progress for Verastem's Avutometinib and Defactinib

TipRanksOct 21 20:50

Truist Financial Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $15

Futu NewsOct 19 17:32

Verastem (VSTM) Receives a Buy From RBC Capital

TipRanksOct 18 19:42

H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $7

Futu NewsOct 18 18:31

Truist Financial Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $15

Futu NewsOct 18 02:32

Verastem Stock: Buy Rating Amid Market Overreaction and Promising Commercial Potential

TipRanksOct 18 02:07

Verastem Analyst Ratings

BenzingaSep 30 19:08

Guggenheim Initiates Verastem(VSTM.US) With Buy Rating, Announces Target Price $13

Futu NewsSep 30 18:33

Outperform Rating and $7 Target for Verastem Amidst LGSOC Treatment Potential and Stock Valuation Opportunity

TipRanksAug 22 14:17

HC Wainwright & Co. Maintains Buy on Verastem, Lowers Price Target to $7

BenzingaAug 13 01:34

Verastem Analyst Ratings

BenzingaAug 13 01:30

Buy Rating Affirmed for Verastem: Financial Stability and Promising Drug Pipeline Fuel Optimism

TipRanksAug 12 18:25

Verastem Analyst Ratings

BenzingaAug 10 03:52

RBC Adjusts Price Target on Verastem to $13 From $16, Maintains Outperform Rating

MT NewswiresAug 10 00:22

Buy Rating Justified by Verastem's Promising LGSOC Drug Prospects and Strong Market Position

TipRanksAug 9 19:54

Mizuho Adjusts Price Target on Verastem to $7 From $36 Following Model Update, Maintains Outperform Rating

MT NewswiresJul 29 17:28

Verastem Analyst Ratings

BenzingaJul 25 01:57

Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), HilleVax, Inc (HLVX) and Schrodinger (SDGR)

TipRanksJul 9 22:08

Verastem Analyst Ratings

BenzingaJul 8 23:44

Truist Securities Maintains Buy on Verastem, Lowers Price Target to $18

BenzingaJul 8 23:44